The HumaPen® Luxura™ HD insulin pen (Eli Lilly and Company, Indianapolis, IN) was originally designed to deliver accurate doses in half-unit increments from 1 to 30 units. Laboratory testing examined the accuracy of the initial 0.5-unit dose within a 95/95% tolerance interval with respect to a specification of ±0.5 unit (±0.005 ml).
Methods:
After priming, operators recorded the first 0.5 unit. Data were analyzed using k-value targets.
Results:
While examining 577 half-unit doses per device lot, test temperature, operator, or test liquid, at least 95% of the doses were accurate with 95% confidence. All data points were within ±0.5 unit (±0.005 ml).
Conclusions:
Dose accuracy of the initial half-unit is achieved with the HumaPen Luxura HD insulin pen.
LteifANSchwenkWF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care.1999;22 (1): 137–40.
2.
International Organization for Standardization. ISO11608-1: 2000 pen-injectors for medical use—Part 1: Pen injector requirements and test methods. Geneva: International Organization for Standardization; 2000.
3.
OdehREOwenDB. Tables for normal tolerance limits, sampling plans, and screening. New York: Marcel Dekker, Inc.; 1980.
4.
BruntonS. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther.2008;10 (4): 247–56.
5.
PfütznerAAsakuraTSommavillaBLeeW. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv.2008;5 (8): 915–25.
6.
MagnottiMARayfieldEJ. An update on insulin injection devices. Insulin.2007;2 (4): 173–81.
